Enhanced Antitumor Efficacy and Reduced Myelosuppression by a Supramolecular Complex Composed of Azocalix[4]arene and...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• Antiangiogenic therapy is a promising cancer treatment but suffers from off-target toxicities like hematotoxicity and myelosuppression due to widespread biodistribution.
• Developing targeted drug delivery systems is crucial to enhance efficacy and minimize side effects in cancer chemotherapy.

Purpose of the Study:

• To develop and evaluate a mannose-modified supramolecular host-guest complex (sunitinib@mannose-modified azocalix[4]arene, ST@ManAC4A) for targeted cancer therapy.
• To assess the tumor-targeting capability, hypoxia-responsive drug release, and antitumor efficacy of ST@ManAC4A.
• To investigate the complex's ability to alleviate thrombocytopenia and myelosuppression.

Main Methods:

• Synthesis and characterization of the sunitinib@mannose-modified azocalix[4]arene (ST@ManAC4A) complex.
• In vitro and in vivo evaluation of antitumor activity, including antiproliferative and apoptosis assays.
• Histopathological, immunohistochemical, and bone marrow analyses to assess therapeutic effects and toxicity.

Main Results:

• ST@ManAC4A demonstrated favorable tumor-targeting, hypoxia-responsive drug release, and accumulation at the tumor site.
• The complex exhibited robust antitumor activity, enhancing antiproliferation and apoptosis in cellular and in vivo models.
• ST@ManAC4A effectively alleviated thrombocytopenia and platelet-related myelosuppression, unlike conventional antiangiogenic agents.

Conclusions:

• The mannose-modified supramolecular host-guest complex (ST@ManAC4A) shows significant potential for improving chemotherapy outcomes.
• This targeted delivery approach enhances therapeutic efficacy while minimizing critical off-target toxicities.
• ST@ManAC4A represents a promising strategy for developing safer and more effective cancer treatments.